Overall verdict
Buy
8.0/10
1-year performance
+56.12%
Score breakdown
Up 56.1% over 1 year, 87% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 4.8/10.
24 analysts, target +0.2% vs the price.
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates ;
and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services ; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics ;
and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Sse
China
CEO
Qing Yang
Founded
2000
Employees
33 834
Revenue / employee
1.3M CNY
Next earnings
October 26, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
173.60 CNY
52-week low
87.09 CNY
1-year performance
56.12%
Rising
Year-to-date performance
78.76%
Rising
Drawdown
-6.45%
Mild pullback
Position in the 52-week range
87% of range
Range: 168.62 CNY - 224.53 CNY (2 methods agree)
The price implies growth of 13.29% per year; the company grows at 25.00%.
Gross margin 52.0%, net margin 40.2%, ROIC 29.5%, ROE 30.3%.
Net margin
40.19%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
51.96%
High
Return on equity (ROE)
30.28%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
29.52%
Exceptional
Free cash flow margin (FCF)
24.79%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.62x
Fair
Margin stability
8.2 pts
Uneven
Revenue to net income
Growth
4.8/10Revenue up 47.7% over 1 year, 22.3% a year over 5, EPS 44.5% a year over 5.
Revenue (trailing 12 months)
54.0Md CNY
Revenue growth (1y)
47.71%
Hyper-growth
Revenue growth (3y)
15.31%
Solid
EPS growth (1y)
26.00%
Strong
EPS CAGR (5y)
44.55%
Exceptional
EPS revisions (3 months)
26.17%
Sharply revised up
Valuation
8.9/10P/E 22.2x, forward P/E 21.1x, EV/EBITDA 18.2x, PEG 0.50. The multiple sits in the 51th percentile of its own 5-year history.
P/E (TTM)
22.2x
Cheap
Sector 51.0x|S&P 23.0x
Forward P/E
21.1x
Fair
EV / EBITDA
18.2x
Fair
Sector 28.4x|S&P 14.5x
PEG
0.50
Growth unpriced
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
197.89 CNY
Undervalued
P/E vs its own 5-year history
among the 49% highest valuations
In line with its history
Market cap
504Md CNY
Financial strength
10.0/10Cash covers 308.3% of the debt, net debt/EBITDA -1.7x.
Net debt / EBITDA
-1.7x
Net cash
Gearing (net debt / equity)
-37.57%
Net cash
Cash
48.0Md CNY
Cash / market cap
9.52%
Solid
Cash / total debt
308.28%
Net cash
Net debt
-32.4Md CNY
Equity
86.4Md CNY
Closed daily candles, 2 years
Last close on September 24, 2026: 162.40 CNY
- MM20158.16
- MM50150.40
- MM200113.35
- RSI 1456.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.35%
200-day average slope, 3 months
+13.89%
50-day average slope, 1 month
+12.40%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.07 % per day
Volatility change
-25.78%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.70 (17) | 7.96 (8) | 59 984 (16) | 29 866 (14) | 22 127 (13) |
| 2027 | 8.97 (18) | 9.43 (8) | 72 070 (18) | 35 518 (15) | 26 565 (15) |
Amounts in millions of CNY, EPS in CNY per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 7.9 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.7 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 5 | A | 6.3 | 6.5 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 4.6 | 4.6 | 38.6Md USD | 47.6x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 175.3 % | ||
| 9 | WAT | 4.5 | 3.3 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
